v3.25.2
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2025
Segment Reporting  
Schedule of segment revenue, segment profit (loss) and significant expenses

Segment information is as follows (dollars in thousands):

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2025

    

2024

    

2025

    

2024

 

 

Revenue

$

5,546

$

4,167

$

33,867

$

259,120

Less:

Discovery department expense (1)(2)

(4,952)

(3,832)

(8,698)

(6,492)

Development department expense (1)(2)

(15,504)

(14,655)

(28,409)

(29,426)

General and administrative expenses (1)

(5,890)

(5,051)

(11,425)

(14,975)

Employee wages and benefits - discovery (2)

(2,188)

(1,808)

(4,515)

(3,677)

Employee wages and benefits - development (2)

(4,658)

(5,268)

(10,142)

(11,646)

Employee wages and benefits - general and administrative

(3,483)

(3,402)

(7,315)

(7,092)

Stock-based compensation expense

(10,912)

(8,944)

(24,714)

(18,296)

Other segment items (3)

36

97

118

78

Interest income

7,406

7,404

14,979

11,780

Income tax (expense) benefit

(172)

676

(172)

(2,650)

Segment (loss) profit

$

(34,771)

$

(30,616)

$

(46,426)

$

176,724

Reconciliation of (loss) profit

Adjustments and reconciling items

$

$

$

$

Consolidated net (loss) income

$

(34,771)

$

(30,616)

$

(46,426)

$

176,724

(1) Amounts exclude employee wages and benefits, stock-based compensation and expense allocations.

(2) As of April 1, 2025, the information regularly provided to the CODM was changed to reclassify pre-clinical expenses from development expense to discovery expense. Prior period segment information has been recast to reflect this change.

(3) Other segment items include foreign currency related income (expense) and other miscellaneous income (expense).